

**CSE: IWIN OTC: IWINF FRA: 97X**

**N E W S R E L E A S E**

**IRWIN NATURALS TO FILE Q4 AND FULL YEAR RESULTS FOR FISCAL 2021**

**Conference Call on Tuesday, May 3, 2022 at 2:00pm EST**

**LOS ANGELES, California, May 3, 2022 / CNW / – Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”)**today announced the Company will file its results for the fiscal fourth quarter and full year 2021, the period ended December 31, 2021, on Tuesday May 3, 2022 on [www.sedar.com](http://www.sedar.com).

**Conference call**

CEO Klee Irwin and CFO Philippe Faraut will be hosting a conference call that same day at noon (EST) to discuss the results, as well as the Company’s strategy and execution going forward.

Details for participants to listen to the call are as follows:

|  |
| --- |
| **Conference Call Participant Details** |
| **Date & time** | May 3, 2022 at 2:00 pm EST |
| **Zoom Meeting ID:** | 830 0425 3799 |
| **Canada:** | 1-647-558-0588 |
| **North America:** | 1-646-558-8656 |
| **Zoom Meeting URL:** |  <https://us02web.zoom.us/j/83004253799> |

**About Irwin Naturals**

Irwin Naturals Inc. is a household name and best-in-class herbal supplement formulator since 1994 that is leveraging its brand to enter the cannabis and psychedelic industries. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years[[1]](#footnote-1). Irwin’s growing portfolio of herbal products are available in more than 100,000 retail doors across North America, where nearly 100 million people know the Irwin Naturals brand[[2]](#footnote-2). In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust to become one of the first household name brands to offer THC-based products and psychedelic mental health treatment.

For investor-related information about the Company, please visit [ir.irwinnaturals.com/](https://ir.irwinnaturals.com/)

**To contact the Company’s Investor Relations department, please** call toll-free at (800) 883-4851 **or send an email to** Investors@IrwinNaturals.com**.**

**Regulatory Overview**

**The following is a brief summary of regulatory matters concerning ketamine in the United States (“US”). Under the Controlled Substances Act (21 U.S.C. § 811) (the "CSA"),** k**etamine is currently a Schedule III drug as well as being listed under the associated Narcotic Control Regulations, and psilocybin is currently a Schedule I drug.**

Most US States have enacted Controlled Substances Acts (“**State CSAs**”) which regulate the possession, use, sale, distribution, and manufacture of specified drugs or categories of drugs and establish penalties for State CSA violations and form the basis for much state and local drug laws enforcement activity. State CSAs have either adopted drug schedules identical or similar to the federal CSA schedules or, in some instances, have incorporated the federal scheduling mechanism. Among other requirements, some US States have established a prescription drug monitoring or review programs collect information about prescription and dispensing of controlled substances for the purposes of monitoring, analysis and education.

In the United States, facilities holding or administering controlled substances must be registered with the US Drug Enforcement Agency ("**DEA**") to perform this activity. As such, medical professionals and/or the clinics in which they operate, as applicable, are also required to have a DEA license to obtain and administer ketamine (a "**DEA License**"). While ketamine is a controlled substance in the United States, it is approved for general anesthetic induction under the US Food, Drug, and Cosmetic Act. Once a drug is approved for use, physicians may prescribe that drug for uses that are not described in the product’s labelling or that differ from those tested by the manufacturer and approved by the Food and Drug Administration (the "**FDA**"). Licensed medical practitioners may prescribe ketamine legally in Canada or the United States where they believe it will be an effective treatment in their professional judgment.

Please see Irwin’s filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US THC industry.

“Klee Irwin”

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Klee Irwin

Chief Executive Officer

T: 310-306-3636 investors@irwinnaturals.com

**Forward-Looking Information**

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as "may", "will", "would", "could", "should", "believes", "estimates", "projects", "potential", "expects", "plans", "intends", "anticipates", "targeted", "continues", "forecasts", "designed", "goal", or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

1. Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs. [↑](#footnote-ref-1)
2. Based on a formal Company survey with a sample size of 500 randomly selected adults. [↑](#footnote-ref-2)